Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Nitric Oxide in Cystic Fibrosis
NCT02498535Phase 2Terminated
- Sponsor
- Novoteris LLC
- Start
- Feb 2017
- Primary completion
- Jun 2020
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 2
01
Overview
A Phase 2 trial of nitric oxide in cystic fibrosis (CF), sponsored by Novoteris LLC. Started Feb 2017; status: terminated.
02
Drugs
nitric oxide
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02498535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02498535.